Microbion Corporation

[On Demand]
Microbion is a clinical-stage pharmaceutical company developing an entirely new class of therapeutic compounds for treating chronic, life-threatening, and orphan diseases. Our lead drug candidate, pravibismane, offers disruptive therapeutic potential through a novel mechanism of action, broad spectrum potency against multi-drug resistant bacteria/superbugs and fungal pathogens, and an unprecedented ability to prevent and eradicate bacterial biofilms.
Multiple pravibismane formulations are under development to target specialty markets representing over ~$4B in peak annual sales opportunity in the U.S. This includes inhaled pravibismane for treatment of Cystic Fibrosis and Nontuberculous Mycobacteria lung infections, and topical/local pravibismane for treatment of chronic wounds and orthopedic infections. Pravibismane’s unique potential has been validated through ~$27M in non-dilutive grants awarded to-date from CARB-X, Cystic Fibrosis Foundation, and and the U.S. NIH, Army, and Navy.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Inhaled pravibismane for CF and NTM lung infections; Topical for chronic wound tx.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Executive Officer
Microbion Corporation